Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001493152-24-044473

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 12, 2024 172.32M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $6.38M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $8.84M
Current Liabilities Q3 2024 · Sep 30, 2024 $44.56K
Current Liabilities Q3 2024 · Dec 31, 2023 $665.16K
Total Liabilities Q3 2024 · Sep 30, 2024 $3.04M
Total Liabilities Q3 2024 · Dec 31, 2023 $3.67M
Current Assets Q3 2024 · Sep 30, 2024 $6.45M
Current Assets Q3 2024 · Dec 31, 2023 $8.95M
Total Assets Q3 2024 · Sep 30, 2024 $6.45M
Total Assets Q3 2024 · Dec 31, 2023 $8.95M
Shares Diluted Q3 2024 · Sep 30, 2023 172.01M sh
Shares Diluted Q3 2024 · Sep 30, 2023 171.93M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$2M
Stockholders Equity Q3 2024 · Sep 30, 2023 $6.45M
Stockholders Equity Q3 2024 · Jun 30, 2023 $7.11M
Stockholders Equity Q3 2024 · Mar 31, 2023 $7.76M
Stockholders Equity Q3 2024 · Dec 31, 2022 $8.3M
Eps Diluted Q3 2024 · Sep 30, 2023 $0.00
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.01
Eps Basic Q3 2024 · Sep 30, 2023 $0.00
Eps Basic Q3 2024 · Sep 30, 2023 −$0.01
Sga Expense Q3 2024 · Sep 30, 2023 $498.76K
Sga Expense Q3 2024 · Sep 30, 2023 $1.44M
Rd Expense Q3 2024 · Sep 30, 2023 $260.77K
Rd Expense Q3 2024 · Sep 30, 2023 $696.16K
Net Income Q3 2024 · Sep 30, 2023 −$664.76K
Net Income Q3 2024 · Sep 30, 2023 −$1.86M
Net Income Q3 2024 · Jun 30, 2023 −$654.52K
Net Income Q3 2024 · Mar 31, 2023 −$539.6K
Operating Income Q3 2024 · Sep 30, 2023 −$759.53K
Operating Income Q3 2024 · Sep 30, 2023 −$2.13M